ArticleBiologics : targets & therapy2008
Adalimumab for the treatment of Crohn's disease.
Article in Biologics : targets & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis.European journal of medical research · 2022Pooled it
- Adalimumab for maintenance of remission in Crohn's disease.The Cochrane database of systematic reviews · 2020Pooled it
- Adalimumab for induction of remission in Crohn's disease.The Cochrane database of systematic reviews · 2019Pooled it
- Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials.European journal of clinical pharmacology · 2014Pooled it
- Biodistribution of Drug/ADA Complexes: The Impact of Immune Complex Formation on Antibody Distribution.The AAPS journal · 2024Article
- Comparison of Timing to Develop Anti-Drug Antibodies to Infliximab and Adalimumab Between Adult and Pediatric Age Groups, Males and Females.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn's Disease.Cureus · 2021Article
- Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil.World journal of gastroenterology · 2021Article
- Medical Management of Crohn's Disease.Cureus · 2020Review
- Body Weight as a Determining Factor in the Predominance of Adverse Drug Reactions Induced by Fixed-Dose Adalimumab Injections in Female Patients in a Korean Hospital Setting.Journal of clinical medicine · 2020Article
- Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease.Therapeutic advances in gastroenterology · 2020Article
- Stromal cells from perinatal and adult sources modulate the inflammatory immune response in vitro by decreasing Th1 cell proliferation and cytokine secretion.Stem cells translational medicine · 2020Article
- Dermal Lesions and Skin Cancer in Patients with Inflammatory Bowel Disease Receiving Immunosuppressive TherapyAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.World journal of gastroenterology · 2018Review
- Severe Crohn's Disease Manifestations in a Child with Cystathionine β-Synthase Deficiency.ACG case reports journal · 2018Article
- Insights on the use of biosimilars in the treatment of inflammatory bowel disease.World journal of gastroenterology · 2017Review
- Inflammatory bowel disease: clinical aspects and treatments.Journal of inflammation research · 2014Review
- Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn's diseasE Questionnaire (SPACE-Q(©)).Patient preference and adherence · 2014Article
- New and emerging treatments for ulcerative colitis: a focus on vedolizumab.Biologics : targets & therapy · 2013Article
- Immunogenicity of protein therapeutics: The key causes, consequences and challenges.Self/nonself · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCrohn's disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing-remitting course with trans-mural inflammation of potentially any section of the digestive tract. Adalimumab (ADA) is a subcutaneously administered, recombinant, fully human, IgG1 monoclonal antibody that binds with high affinity and specificity to human TNF-alpha, thus modulating its biologic functions and its proinflammatory effects.
aimsTo review the available data on ADA in CD for biological properties, efficacy, and safety.
methodsElectronic searches were conducted using the Pubmed and SCOPUS databases from the earliest records to April 2008. The search terms used were "adalimumab", "anti-TNF", "TNF-alpha", "biologicals", "inflammatory bowel disease", and "Crohn's disease". Reference lists of all relevant articles were searched for further studies.
resultsAvailable studies suggest that ADA has the potential to induce and maintain clinical response and remission in moderate-severe CD, both in anti-TNF-naïve patients and in subjects who lost their response and/or became intolerant to infliximab (IFX). ADA seems also effective in maintaining corticosteroid-free remission and obtaining complete fistula closure (although no specific randomized trials are available). No concomitant immunosuppressors seem to be necessary. Side effects appear similar to IFX, while site-injection reactions are frequent and specific. Data on immunogenicity and its clinical impact are uncertain.
conclusionsADA appears to be effective in inducing and maintain clinical remission in CD, including patients not manageable with IFX. Successive clinical practice and further on going trials will confirm a positive role for ADA as a new anti-TNF treatment in CD. The impact on clinical management or on resources should be more studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.